A tumor microenvironment biomarker study identified elevated CD93 as correlating with immunosuppression and reduced immunotherapy efficacy in advanced non-small cell lung cancer. Using integrated analyses of public databases plus validation on clinical specimens, the investigators reported CD93-positive endothelial and myeloid populations as key sources. High CD93 expression aligned with lower CD8 infiltration and higher FOXP3, while patients with poorer immunotherapy response showed relatively higher CD93 levels. The study also pointed to disease stage and tumor type patterns, including trends in overall survival for lung adenocarcinoma. If validated prospectively, CD93 could function as a stratification biomarker to guide treatment selection in settings where durable response rates remain limited.